Conclusions
Monotherapy with metformin was associated with durable glycemic control in approximately
half of children and adolescents with type 2 diabetes. The addition of
rosiglitazone, but not an intensive lifestyle intervention, was superior to metformin
alone. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases
and others; TODAY ClinicalTrials.gov number, NCT00081328.)